CompaniesShionogi

Shionogi

active

Osaka, Japan

Founded 1919

Website

About

Small Molecules, Injectors

Areas of Focus

Categories

Small Molecule PharmaceuticalJapan

Clinical Trials (131)

View all

Total Trials

131

As Lead Sponsor

As Collaborator

Total Enrollment

43,090

By Phase

PHASE2: 32PHASE1: 47PHASE4: 4PHASE3: 37PHASE1/PHASE2: 5NA: 2

By Status

COMPLETED: 109RECRUITING: 9TERMINATED: 5NOT_YET_RECRUITING: 3UNKNOWN: 3ENROLLING_BY_INVITATION: 1APPROVED_FOR_MARKETING: 1

Clinical Trials Pipeline130 trials

Early Phase 1

Phase 1

Phase 2

Phase 3

Phase 4

Phase 1/2

Phase 2/3

N/A

Phase

Status

Role

Condition

2000

2001

2002

2003

2004

2005

2006

2007

2008

2009

2010

2011

2012

2013

2014

2015

2016

2017

2018

2019

2020

2021

2022

2023

2024

2025

2026

2027

2028

2029

2030

2031

Today

NCT00033215

A Phase 1 Study of S-3304 in Patients With Solid Tumors

Phase: Phase 1

Role: Lead Sponsor

Start: Nov 30, 2001

Completion: Mar 12, 2003

NCT00046332

A Study Comparing 4 Doses Of GW810781 Versus Placebo In HIV-Infected Patients

Phase: Phase 2

Role: Collaborator

Start: Jun 30, 2002

Completion: Jan 31, 2003

NCT00078390

Study of S-3304 in Patients With Locally Advanced Non-Small Cell Lung Cancer

Phase: Phase 1/2

Role: Lead Sponsor

Start: Feb 28, 2003

Completion: Oct 26, 2006

NCT00329160

Rosuvastatin in the Long-term Treatment of Hypercholesterolaemic Subjects With Coronary Heart Disease

Phase: Phase 4

Role: Collaborator

Start: Oct 31, 2005

Completion: Oct 31, 2008

NCT00276094

A Clinical Study to Evaluate Ospemifene in the Treatment of Vulvar and Vaginal Atrophy in Postmenopausal Women

Phase: Phase 3

Role: Lead Sponsor

Start: Jan 31, 2006

Completion: Dec 31, 2007

NCT00628121

Clinical Pharmacological Study of GnRH Antagonist, Cetrorelix for Healthy Female Volunteer

Phase: N/A

Role: Collaborator

Start: Apr 30, 2006

Completion: Feb 28, 2007

NCT01586364

Long-Term Safety of Ospemifene 60 mg Oral Daily Dose for the Treatment of Vulvar and Vaginal Atrophy (VVA) in Postmenopausal Women Without a Uterus

Phase: Phase 3

Role: Lead Sponsor

Start: May 8, 2006

Completion: Dec 22, 2008

NCT01585558

Long-Term Safety of 30 mg and 60 mg Oral Daily Dose of Ospemifene in the Treatment of Vulvar and Vaginal Atrophy (VVA) in Postmenopausal Women With Intact Uterus

Phase: Phase 3

Role: Lead Sponsor

Start: May 16, 2006

Completion: Sep 18, 2008

NCT00491894

Safety and Efficacy Study of Oral Glycopyrrolate Liquid for the Treatment of Pathologic (Chronic Moderate to Severe) Drooling in Pediatric Patients 3 to 18 Years of Age With Cerebral Palsy or Other Neurologic Conditions

Phase: Phase 3

Role: Lead Sponsor

Start: Mar 31, 2007

Completion: Jun 30, 2008

NCT00459745

A Study to Evaluate Daily Pravastatin, Fenofibrate or Pravafen in the Treatment of Combined Hyperlipidemia

Phase: Phase 3

Role: Lead Sponsor

Start: Apr 30, 2007

Completion: Jul 31, 2009

NCT00747929

Phase IIb One Year Efficacy and Safety Study of S-2367 in Obese Subjects With Reduced Calorie Diet

Phase: Phase 2

Role: Lead Sponsor

Start: Jun 30, 2007

Completion: Jan 31, 2009

NCT00748605

Phase IIb One Year Efficacy and Safety Study of S-2367 in Obese Subjects With Initial 6-Week Low Calorie Diet

Phase: Phase 2

Role: Lead Sponsor

Start: Jun 30, 2007

Completion: Jan 31, 2009

NCT00697710

A Phase Ib/IIa, Double-Blind, Randomized Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of S-777469 in Subjects With Atopic Dermatitis

Phase: Phase 1/2

Role: Lead Sponsor

Start: Jul 31, 2007

Completion: Sep 30, 2008

NCT00630539

A Clinical Study to Evaluate the Efficacy and Safety of Ospemifene in the Treatment of Vulvar and Vaginal Atrophy (VVA) in Postmenopausal Women

Phase: Phase 2

Role: Lead Sponsor

Start: Aug 31, 2007

Completion: Feb 29, 2008

NCT00566982

A Clinical Study to Evaluate the Safety of Ospemifene

Phase: Phase 3

Role: Lead Sponsor

Start: Oct 31, 2007

Completion: Jul 31, 2009

NCT00552175

A Study for the Treatment of Diabetic Peripheral Neuropathic Pain

Phase: Phase 3

Role: Collaborator

Start: Nov 30, 2007

Completion: Mar 31, 2009

NCT00723190

Open-Label, Chronic Exposure, Safety Study of CLONICEL (Clonidine HCl Sustained Release) in Children and Adolescents With Attention Deficit Hyperactivity Disorder (ADHD)

Phase: Phase 3

Role: Lead Sponsor

Start: Jan 31, 2008

Completion: Jun 30, 2010

NCT00641719

A Long-term Study for the Treatment of Painful Diabetic Neuropathy

Phase: Phase 3

Role: Collaborator

Start: Mar 31, 2008

Completion: Mar 31, 2010

NCT00703573

A Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of 2 Doses of S-777469 in Patients With Atopic Dermatitis

Phase: Phase 2

Role: Lead Sponsor

Start: May 31, 2008

Completion: Dec 31, 2009

NCT00708110

Phase IIa Dose-ranging Study of GSK1349572 in HIV-1 Infected Adults

Phase: Phase 2

Role: Collaborator

Start: Jun 30, 2008

Completion: Aug 31, 2008

NCT00812318

Healthy Volunteer Study To Assess The Bioavailability of GSK1265744 When Administered Orally Either When Fasted or Following a Meal.

Phase: Phase 1

Role: Collaborator

Start: Jun 30, 2008

Completion: Aug 31, 2008

NCT00729469

Efficacy and Safety of Ospemifene in the Treatment of Moderate to Severe Vaginal Dryness and Vaginal Pain Associated With Sexual Activity

Phase: Phase 3

Role: Lead Sponsor

Start: Jul 31, 2008

Completion: Aug 31, 2009

NCT00788528

Open-Label Extension (OLE) Study for Safety and Efficacy of Velneperit (S-2367) in Obese Subjects

Phase: Phase 2

Role: Lead Sponsor

Start: Aug 31, 2008

Completion: Mar 31, 2010

NCT00774111

GSK1349572 Drug Interaction Study With Etravirine

Phase: Phase 1

Role: Collaborator

Start: Oct 31, 2008

Completion: Dec 31, 2008

NCT00774735

GSK1349572 Drug Interaction Study With Protease Inhibitors

Phase: Phase 1

Role: Collaborator

Start: Oct 31, 2008

Completion: Dec 31, 2008

NCT00858455

A Study to Evaluate the Effect of Antacid and Multivitamin and Mineral Tablet on the Study Drug GSK1349572

Phase: Phase 1

Role: Collaborator

Start: Jan 31, 2009

Completion: Mar 31, 2009

NCT00828763

GSK1349572 Mass Balance Study

Phase: Phase 1

Role: Collaborator

Start: Feb 28, 2009

Completion: Mar 31, 2009

NCT00867152

GSK1349572 Drug Interaction With Etravirine and Either Darunavir/Ritonavir or Lopinavir/Ritonavir

Phase: Phase 1

Role: Collaborator

Start: Apr 30, 2009

Completion: May 31, 2009

NCT00883935

GSK1349572 Drug Interaction Study With Atazanavir/Ritonavir and Atazanavir

Phase: Phase 1

Role: Collaborator

Start: Apr 30, 2009

Completion: Jun 30, 2009

NCT00920426

Study to Compare the Safety and Anti-HIV Effect of GSK1265744 Versus Placebo in HIV-1 Infected Adults (ITZ112929)

Phase: Phase 2

Role: Collaborator

Start: Jun 9, 2009

Completion: Aug 13, 2009

NCT00951015

A Dose Ranging Trial of GSK1349572 and 2 NRTI in HIV-1 Infected, Therapy Naive Subjects

Phase: Phase 2

Role: Collaborator

Start: Jul 30, 2009

Completion: Dec 22, 2016

NCT00951015

NCT00942136

GSK1349572 Proton Pump Inhibitor Drug Interaction and Supratherapeutic Dose Study

Phase: Phase 1

Role: Collaborator

Start: Jul 31, 2009

Completion: Sep 30, 2009

NCT00996021

Study to Assess Cardiac Conduction of GSK1349572

Phase: Phase 1

Role: Collaborator

Start: Sep 30, 2009

Completion: Dec 31, 2009

NCT03897413

Effect of Food and Calcium on Pharmacokinetics of a Single Dose of S-888711 in Healthy Adult Volunteers

Phase: Phase 1

Role: Lead Sponsor

Start: Nov 6, 2009

Completion: Dec 23, 2009

NCT01068925

Drug Interaction Study Between GSK1349572 and Tipranavir/Ritonavir in Healthy Volunteers

Phase: Phase 1

Role: Collaborator

Start: Feb 15, 2010

Completion: Apr 5, 2010

NCT01098526

GSK1349572 Drug Interaction Study With Efavirenz

Phase: Phase 1

Role: Collaborator

Start: Mar 16, 2010

Completion: May 26, 2010

NCT01054443

A Study to Investigate the Efficacy and Safety of Lusutrombopag (S-888711) Tablets Administered to Adults With Immune Thrombocytopenia (ITP)

Phase: Phase 2

Role: Lead Sponsor

Start: Mar 18, 2010

Completion: Nov 24, 2010

NCT01129024

An Open-label Safety Study of Lusutrombopag (S-888711) in Adults With Chronic Immune Thrombocytopenia (ITP)

Phase: Phase 2

Role: Lead Sponsor

Start: Apr 29, 2010

Completion: Jun 30, 2011

NCT01126970

Double-Blind, Multi-Center, Randomized Study to Assess the Efficacy and Safety of Velneperit (S-2367) and Orlistat Administered Individually or Combined With a Reduced Calorie Diet (RCD) in Obese Subjects

Phase: Phase 2

Role: Lead Sponsor

Start: Apr 30, 2010

Completion: Feb 28, 2011

NCT01122030

Study to Evaluate the Safety and Efficacy of Naldemedine (S-297995) for the Treatment of Opioid-Induced Bowel Dysfunction in Subjects With Chronic Pain

Phase: Phase 2

Role: Lead Sponsor

Start: May 19, 2010

Completion: Mar 22, 2011

NCT01154348

Study to Assess Safety and Pharmacokinetics of Double-Blind S-707106 Alone and in Combination With Open-Label Metformin in Patients With Type 2 Diabetes Mellitus

Phase: Phase 1

Role: Lead Sponsor

Start: Jun 30, 2010

Completion: Dec 31, 2010

NCT01227824

A Trial Comparing GSK1349572 50mg Once Daily to Raltegravir 400mg Twice Daily

Phase: Phase 3

Role: Collaborator

Start: Oct 19, 2010

Completion: Dec 27, 2016

NCT01227824

NCT01231516

A Study of GSK1349572 Versus Raltegravir (RAL) With Investigator Selected Background Regimen in Antiretroviral-Experienced, Integrase Inhibitor-Naive Adults

Phase: Phase 3

Role: Collaborator

Start: Oct 26, 2010

Completion: Feb 2, 2021

NCT01231516

NCT01240759

Safety and Efficacy of S-707106 in Subjects With Type 2 Diabetes Mellitus and Inadequate Glycemic Control With Metformin Therapy

Phase: Phase 2

Role: Lead Sponsor

Start: Oct 31, 2010

Completion: Jan 31, 2012

NCT01214993

A Phase 1, Open Label, Placebo-Controlled Study to Evaluate the Effect of GSK1349572 on Iohexol and Para-Aminohippurate Clearance in Healthy Subjects

Phase: Phase 1

Role: Collaborator

Start: Oct 31, 2010

Completion: Nov 30, 2010

NCT01231529

GSK1349572 Hepatic Impairment Study

Phase: Phase 1

Role: Collaborator

Start: Nov 19, 2010

Completion: Jun 4, 2011

NCT01263015

A Trial Comparing GSK1349572 50mg Plus Abacavir/Lamivudine Once Daily to Atripla (Also Called The SINGLE Trial)

Phase: Phase 3

Role: Collaborator

Start: Feb 1, 2011

Completion: Dec 3, 2015

NCT01263015

NCT01332565

A Study to Investigate the Pharmacokinetics, Safety and Tolerability of GSK1349572 (Dolutegravir, DTG) in Healthy Japanese Subjects

Phase: Phase 1

Role: Collaborator

Start: Apr 30, 2011

Completion: Jun 30, 2011

NCT01231542

Phase 1, Open Label, Two Arm, Fixed Sequence Study to Evaluate the Effect of Rifampin and Rifabutin on GSK1349572 Pharmacokinetics in Healthy Male and Female Volunteers

Phase: Phase 1

Role: Collaborator

Start: May 31, 2011

Completion: Dec 31, 2011

NCT01328041

A Study to Assess Dolutegravir in HIV-infected Subjects With Treatment Failure on an Integrase Inhibitor Containing Regimen.

Phase: Phase 3

Role: Collaborator

Start: May 31, 2011

Completion: May 31, 2015

NCT01353716

Dolutegravir Renal Impairment Study

Phase: Phase 1

Role: Collaborator

Start: Jun 30, 2011

Completion: Apr 30, 2012

NCT01366547

Relative Bioavailability Study of Two New Dolutegravir/Abacavir/Lamivudine Fixed Dose Combination Tablets

Phase: Phase 1

Role: Collaborator

Start: Jun 30, 2011

Completion: Jul 31, 2011

NCT01382238

Relative Bioavailability Study of a Pediatric Granule Formulation of Dolutegravir

Phase: Phase 1

Role: Collaborator

Start: Jun 30, 2011

Completion: Aug 31, 2011

NCT01443403

A Study of Naldemedine (S-297995) for the Treatment of Opioid-Induced Constipation in Adults With Non-Malignant Chronic Pain Receiving Opioid Therapy

Phase: Phase 2

Role: Lead Sponsor

Start: Aug 17, 2011

Completion: Aug 22, 2012

NCT01425099

Drug Interaction Study Between Dolutegravir and Prednisone

Phase: Phase 1

Role: Collaborator

Start: Sep 30, 2011

Completion: Oct 31, 2011

NCT01467531

A Study to Evaluate the Pharmacokinetics and Safety of GSK1265744 and Rilpivirine and Dolutegravir and Rilpivirine in Healthy Adult Subjects

Phase: Phase 1

Role: Collaborator

Start: Nov 30, 2011

Completion: Feb 29, 2012

NCT01467518

Methadone-Dolutegravir (DTG - GSK1349572) Drug Interaction Study.

Phase: Phase 1

Role: Collaborator

Start: Dec 31, 2011

Completion: Feb 29, 2012

NCT01498861

Drug Interaction Study Between Dolutegravir and an Oral Contraceptive Containing Norgestimate and Ethinylestradiol

Phase: Phase 1

Role: Collaborator

Start: Dec 31, 2011

Completion: Mar 31, 2012

NCT01499199

A Study of the Pharmacokinetics and Antiviral Activity of Dolutegravir in the Central Nervous System in HIV-1 Infected ART-naive Subjects

Phase: Phase 3

Role: Collaborator

Start: Jan 31, 2012

Completion: May 31, 2014

NCT01563328

A Study to Evaluate the Effect of Boceprevir and Telaprevir on Dolutegravir Pharmacokinetics in Healthy Adult Subjects (ING115697).

Phase: Phase 1

Role: Collaborator

Start: Mar 1, 2012

Completion: May 1, 2012

NCT01552057

A Study of Duloxetine in Fibromyalgia

Phase: Phase 3

Role: Collaborator

Start: Mar 31, 2012

Completion: Dec 31, 2013

NCT01568892

Study Assessing Dolutegravir in HIV-1 Infected Subjects With Virus Resistant to Raltegravir and/or Elivitegravir

Phase: Phase 3

Role: Collaborator

Start: Apr 18, 2012

Completion: Dec 16, 2013

NCT01592617

Phase II Study of S-488410 to Treat Non-small Cell Lung Cancer

Phase: Phase 2

Role: Collaborator

Start: May 31, 2012

Completion: Sep 30, 2015

NCT01621191

An Extension Study of Duloxetine in Fibromyalgia (Extension of F1J-JE-HMGZ, NCT01552057)

Phase: Phase 3

Role: Collaborator

Start: Jun 30, 2012

Completion: Feb 28, 2014

NCT01622790

Evaluation of the Bioequivalence of a Combined Formulated Tablet

Phase: Phase 1

Role: Collaborator

Start: Jun 30, 2012

Completion: Aug 31, 2012

NCT01651871

Combination Study Of S-555739/Cetirizine HCl In Adult Patients With Seasonal Allergic Rhinitis

Phase: Phase 2

Role: Lead Sponsor

Start: Jul 31, 2012

Completion: May 31, 2013

NCT01855919

A Study of Duloxetine (LY248686) in Participants With Chronic Low Back Pain

Phase: Phase 3

Role: Collaborator

Start: May 31, 2013

Completion: Jul 31, 2014

NCT01965158

Efficacy and Safety of Naldemedine in the Treatment of Opioid-induced Constipation

Phase: Phase 3

Role: Lead Sponsor

Start: Aug 29, 2013

Completion: Jan 22, 2015

NCT01965652

Long Term Safety of Naldemedine

Phase: Phase 3

Role: Lead Sponsor

Start: Sep 24, 2013

Completion: Jan 12, 2016

NCT01914666

An Open Label Extension Study of Duloxetine (LY248686) in Participants With Chronic Low Back Pain

Phase: Phase 3

Role: Collaborator

Start: Sep 30, 2013

Completion: Dec 31, 2014

NCT01993940

Efficacy and Safety of Naldemedine in Treating Opioid-induced Constipation

Phase: Phase 3

Role: Lead Sponsor

Start: Nov 4, 2013

Completion: Jun 9, 2015

NCT02096614

Investigator Initiated Phase 1 Study of TBI-1201

Phase: Phase 1

Role: Collaborator

Start: Apr 30, 2014

Completion: Mar 31, 2021

NCT02096614

NCT02248480

A Study of Duloxetine (LY248686) in Participants With Chronic Osteoarthritis and Knee Pain in Japan

Phase: Phase 3

Role: Collaborator

Start: Oct 31, 2014

Completion: Jun 30, 2015

NCT02335346

An Extension Study of Duloxetine in Osteoarthritis and Knee Pain (Extension of F1J-JE-HMGX, NCT02248480)

Phase: Phase 3

Role: Collaborator

Start: Jan 31, 2015

Completion: Mar 31, 2016

NCT02321800

A Study of Efficacy and Safety of Intravenous Cefiderocol (S-649266) Versus Imipenem/Cilastatin in Complicated Urinary Tract Infections

Phase: Phase 2

Role: Lead Sponsor

Start: Feb 5, 2015

Completion: Aug 16, 2016

NCT02366546

Investigator Initiated Phase 1 Study of TBI-1301

Phase: Phase 1

Role: Collaborator

Start: Mar 31, 2015

Completion: Not specified

NCT02366546

NCT02410369

Study of S-588410 After Adjuvant Chemotherapy for Completely Resected Non-small- Cell Lung Cancer

Phase: Phase 2

Role: Collaborator

Start: Mar 31, 2015

Completion: Sep 30, 2021

NCT02410369

NCT02417935

A Study of Duloxetine (LY248686) in Participants With Diabetic Peripheral Neuropathic Pain (DPNP)

Phase: Phase 4

Role: Collaborator

Start: Apr 30, 2015

Completion: May 13, 2017

NCT02389621

Safety and Efficacy Study of Lusutrombopag for Thrombocytopenia in Patients With Chronic Liver Disease Undergoing Elective Invasive Procedures

Phase: Phase 3

Role: Lead Sponsor

Start: Jun 15, 2015

Completion: Apr 19, 2017

NCT02549846

AdminiStration of Statin On Acute Ischemic stRoke patienT Trial

Phase: Phase 4

Role: Collaborator

Start: Sep 30, 2015

Completion: Mar 31, 2017

NCT02638337

Study to Evaluate Ospemifene in Patients With Moderate to Severe Vaginal Dryness Due to Menopause

Phase: Phase 3

Role: Lead Sponsor

Start: Jan 26, 2016

Completion: Jul 5, 2017

NCT02714595

Study of Cefiderocol (S-649266) or Best Available Therapy for the Treatment of Severe Infections Caused by Carbapenem-resistant Gram-negative Pathogens

Phase: Phase 3

Role: Lead Sponsor

Start: Sep 7, 2016

Completion: Apr 22, 2019

NCT02954354

A Study of S-033188 (Baloxavir Marboxil) Compared With Placebo or Oseltamivir in Otherwise Healthy Patients With Influenza

Phase: Phase 3

Role: Lead Sponsor

Start: Dec 8, 2016

Completion: Apr 24, 2017

NCT02949011

Study of S-033188 (Baloxavir Marboxil) Compared With Placebo or Oseltamivir in Patients With Influenza at High Risk of Influenza Complications

Phase: Phase 3

Role: Lead Sponsor

Start: Jan 11, 2017

Completion: Apr 20, 2018

NCT03028870

A Study to Evaluate the Analgesic Efficacy and Safety of V120083 in Subjects With Osteoarthritis (OA) of the Knee

Phase: Phase 2

Role: Collaborator

Start: Mar 14, 2017

Completion: Nov 21, 2017

NCT03032380

Clinical Study of Cefiderocol (S-649266) for the Treatment of Nosocomial Pneumonia Caused by Gram-negative Pathogens

Phase: Phase 3

Role: Lead Sponsor

Start: Oct 24, 2017

Completion: Apr 1, 2019

NCT03315793

A Study of Duloxetine (LY248686) in Japanese Children and Adolescents With Depressive Disorder

Phase: Phase 3

Role: Lead Sponsor

Start: Dec 4, 2017

Completion: Nov 8, 2019

NCT03395353

A Study of Duloxetine (LY248686) in the Treatment of Japanese Children and Adolescents With Depressive Disorder

Phase: Phase 3

Role: Lead Sponsor

Start: Jan 29, 2018

Completion: Jul 4, 2020

NCT03862040

Cefiderocol Concentrations in the Lungs of Hospitalized Patients With Bacterial Pneumonia

Phase: Phase 1

Role: Lead Sponsor

Start: Feb 20, 2019

Completion: Oct 15, 2019

NCT03959332

Study to Assess the Pharmacokinetics, Safety and Tolerability of Baloxavir Marboxil in Healthy Chinese Participants

Phase: N/A

Role: Collaborator

Start: Jun 19, 2019

Completion: Jul 11, 2019

NCT04316689

First-in-human Study of S-588210 (S-488210+S-488211)

Phase: Phase 1

Role: Lead Sponsor

Start: Jul 30, 2019

Completion: Sep 22, 2021

NCT04147715

Evaluation of Safety, Tolerability, Pharmacokinetics, Drug-Drug and Food Interactions of Single and Multiple Doses of S-648414 in Healthy Adults

Phase: Phase 1

Role: Lead Sponsor

Start: Oct 9, 2019

Completion: Sep 29, 2020

NCT03869437

RCT Cefiderocol vs BAT for Treatment of Gram Negative BSI

Phase: Phase 2

Role: Collaborator

Start: Oct 28, 2019

Completion: Jan 29, 2024

NCT04110054

Evaluation of S-600918 in Adults With Refractory Chronic Cough

Phase: Phase 2

Role: Lead Sponsor

Start: Feb 13, 2020

Completion: Dec 28, 2020

NCT04215991

A Study to Assess the Safety, Tolerability, and Pharmacokinetics of Cefiderocol in Hospitalized Pediatric Participants

Phase: Phase 2

Role: Lead Sponsor

Start: Feb 19, 2020

Completion: Sep 17, 2024

NCT04607707

Women's Satisfaction and Adherence to Vulvovaginal Atrophy Treatments

Phase: N/A

Role: Lead Sponsor

Start: Jul 7, 2020

Completion: Apr 30, 2021

NCT04335539

A Study to Assess the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses of Cefiderocol in Hospitalized Pediatric Participants

Phase: Phase 2

Role: Lead Sponsor

Start: Aug 21, 2020

Completion: Feb 6, 2023

NCT04355169

A Study of Naldemedine in Participants Undergoing Surgeries That Include a Bowel Resection or Bowel Transection

Phase: Phase 2

Role: Lead Sponsor

Start: Nov 6, 2020

Completion: Jan 4, 2021

NCT04631354

Study in Healthy Adults to Quantify Lung Deposition and Distribution of Radio-labelled S-770108 Inhalation Powder Formulation Delivered by a Novel Inhaler Device

Phase: Phase 1

Role: Lead Sponsor

Start: Nov 9, 2020

Completion: Dec 21, 2020

NCT05212948

A Study of S-268019 for the Prevention of COVID-19

Phase: Phase 3

Role: Lead Sponsor

Start: Dec 25, 2021

Completion: Jul 19, 2023

NCT05247970

A Study to Assess S-309309 in Healthy and Obese Participants

Phase: Phase 1

Role: Lead Sponsor

Start: Jan 4, 2022

Completion: Nov 1, 2022

NCT04106115

DURvalumab in Combination With S-488210/S-488211 vAccine in Non-muscle Invasive Bladder CancEr

Phase: Phase 1/2

Role: Collaborator

Start: Mar 25, 2022

Completion: May 31, 2029

NCT04106115

NCT05101187

Olorofim Aspergillus Infection Study

Phase: Phase 3

Role: Collaborator

Start: Mar 31, 2022

Completion: Nov 1, 2026

NCT05395104

A Study to Assess the Effect of Cefiderocol on the Pharmacokinetics (PK) of Midazolam in Healthy Participants

Phase: Phase 1

Role: Lead Sponsor

Start: May 24, 2022

Completion: Jul 13, 2022

NCT05101070

S-531011 as Monotherapy and in Combination With an Immune Checkpoint Inhibitor in Advanced or Metastatic Solid Tumors

Phase: Phase 1/2

Role: Lead Sponsor

Start: May 30, 2022

Completion: Apr 16, 2027

NCT05101070

NCT05789199

Use of Cefiderocol in the Management of Gram-Negative Infections

Phase: N/A

Role: Lead Sponsor

Start: Jul 31, 2022

Completion: Jun 16, 2023

NCT05305547

A Study to Compare S-217622 With Placebo in Non-Hospitalized Participants With COVID-19

Phase: Phase 3

Role: Lead Sponsor

Start: Aug 3, 2022

Completion: May 24, 2024

NCT05363215

A Study to Assess S-217622 in Participants With Renal Impairment and Healthy Participants

Phase: Phase 1

Role: Lead Sponsor

Start: Aug 10, 2022

Completion: Apr 12, 2023

NCT05409911

A Study to Assess S-217622 in Participants With Mild and Moderate Hepatic Impairment and Healthy Control Participants

Phase: Phase 1

Role: Lead Sponsor

Start: Sep 13, 2022

Completion: Apr 25, 2023

NCT05588323

Safety and Pharmacokinetics Study of Naldemedine in Paediatric Participants Receiving Opioids

Phase: Phase 1/2

Role: Lead Sponsor

Start: Jan 4, 2023

Completion: Jun 15, 2026

NCT05897541

Phase 3 Study of S-217622 in Prevention of Symptomatic SARS-CoV-2 Infection

Phase: Phase 3

Role: Lead Sponsor

Start: Jun 9, 2023

Completion: Sep 18, 2024

NCT05925114

Safety and Efficacy Study of S-309309 in Obese Adults

Phase: Phase 2

Role: Lead Sponsor

Start: Jun 21, 2023

Completion: May 17, 2024

NCT05953480

A Phase 2b, Randomized, Double-blind Study of Redasemtide (S-005151) in Adult Participants With Acute Ischemic Stroke

Phase: Phase 2

Role: Lead Sponsor

Start: Jul 14, 2023

Completion: Mar 31, 2026

NCT06106334

Effect of Administration of Itraconazole on the Pharmacokinetics of S-309309 in Healthy Participants

Phase: Phase 1

Role: Lead Sponsor

Start: Nov 15, 2023

Completion: Feb 14, 2024

NCT06270511

A Study to Investigate Different Formulations of S-337395 in Healthy Adult Participants

Phase: Phase 1

Role: Lead Sponsor

Start: Mar 13, 2024

Completion: Jun 19, 2024

NCT06086626

A Study to Assess the Safety, Tolerability, and Pharmacokinetics of Cefiderocol in Hospitalized Neonates and Infants

Phase: Phase 2

Role: Lead Sponsor

Start: Mar 14, 2024

Completion: Mar 31, 2025

NCT06724978

A Study of S-740792 in Healthy Adult Study Participants

Phase: Phase 1

Role: Lead Sponsor

Start: Nov 21, 2024

Completion: Sep 24, 2025

NCT06746051

A Study to Investigate How Respiratory Syncytial Virus (RSV) Infection Develops and Changes Over Time in Pediatric Participants

Phase: N/A

Role: Lead Sponsor

Start: Dec 9, 2024

Completion: Mar 31, 2025

NCT06751017

A Drug-drug Interaction Study of S-892216 Coadministered With Carbamazepime to Healthy Adult Participants

Phase: Phase 1

Role: Lead Sponsor

Start: Dec 17, 2024

Completion: Feb 24, 2025

NCT06775730

A Drug-Drug Interaction Study of S-217622 With Combined Oral Contraceptives in Healthy Adult Female Participants

Phase: Phase 1

Role: Lead Sponsor

Start: Dec 30, 2024

Completion: Apr 3, 2025

NCT06717438

Study of Zatolmilast (BPN14770) in Participants With PPP2R5D Neurodevelopmental Disorder (Jordan's Syndrome [JS])

Phase: Phase 2

Role: Lead Sponsor

Start: May 13, 2025

Completion: Jan 31, 2030

NCT06928051

A Study of S-892216 in Participants With COVID-19

Phase: Phase 2

Role: Lead Sponsor

Start: Jun 6, 2025

Completion: Sep 22, 2025

NCT07038551

Prophylactic Use of Naldemedine on Opioid-induced Nausea and Vomiting in Patients With Cancer: POSEIDON Study

Phase: Phase 4

Role: Collaborator

Start: Jun 6, 2025

Completion: Sep 30, 2027

NCT07011992

A Study to Assess the Effects of BPN14770 on Rosuvastatin

Phase: Phase 1

Role: Lead Sponsor

Start: Jul 18, 2025

Completion: Aug 7, 2025

NCT07093580

Study of S-892216 Long-acting Injectable (LAI) in Healthy Adult Participants

Phase: Phase 1

Role: Lead Sponsor

Start: Jul 29, 2025

Completion: May 26, 2027

NCT07012005

Study of BPN14770 in Participants With Severe Renal Impairment and Healthy Controls

Phase: Phase 1

Role: Lead Sponsor

Start: Aug 25, 2025

Completion: Dec 31, 2025

NCT07018492

Phase 1 Study of BPN14770 in Participants With Hepatic Impairment and Healthy Controls

Phase: Phase 1

Role: Lead Sponsor

Start: Aug 30, 2025

Completion: Dec 31, 2025

NCT07217886

A Study of S-892216-PO in Participants With Renal Impairment and Matched Controls

Phase: Phase 1

Role: Lead Sponsor

Start: Oct 17, 2025

Completion: Jun 5, 2026

NCT07123155

Study of S-606001 as an Add-on to Enzyme Replacement Therapy (ERT) in Participants With Late-onset Pompe Disease (LOPD)

Phase: Phase 2

Role: Lead Sponsor

Start: Oct 30, 2025

Completion: Aug 8, 2027

NCT07214571

A Study of S-337395 in Symptomatic Nonhospitalized Adults With Respiratory Syncytial Virus (RSV) Who Are at High Risk of Progression to Severe Disease

Phase: Phase 2

Role: Lead Sponsor

Start: Dec 1, 2025

Completion: Dec 30, 2026

Hover over trial bars to see details